Publication - Independent report

Review of Access to New Medicines

An independent review to assess the impact of the new approach introduced in 2014 by Scottish Medicines Consortium (SMC).

ABPI	Association of the British Pharmaceutical Industry
ADTC	Area Drug & Therapeutic Committee
BNF	British National Formulary
CMO	Chief Medical Officer
DAD	Detailed Advice Document
EAS	Early Access Schemes
EMA	European Medicines Agency
HIS	Healthcare Improvement Scotland
HTA	Health Technology Assessment
ICER	Incremental Cost Effectiveness Ratio
IPTR	Individual Patient Treatment Request
ISD	Information Services Division
MAS	Managed Access Scheme
NDC	New Drugs Committee
NICE	National Institute for Health and Care Excellence
NMF	New Medicines Fund
NSS	NHS National Services Scotland
PACE	Patient and Clinician Engagement
PACS	Peer Approved Clinical System
PAS	Patient Access Scheme
PASAG	Patient Access Schemes Assessment Group
PHI	Public Health Intelligence
PPRS	Pharmaceutical Price Regulation Scheme
QALY	Quality-Adjusted Life-Year
RCMF	Rare Conditions Medicines Fund
SHTG	Scottish Health Technology Group
SMC	Scottish Medicines Consortium
T&FG	Task and Finish Group

There is a problem

Thanks for your feedback

Was this helpful?

Yes

Your comments

Your feedback helps us to improve this website. Do not give any personal information because we cannot reply to you directly.

Choose a reason for your feedback

Your comments

Your feedback helps us to improve this website. Do not give any personal information because we cannot reply to you directly.

Yes, but

Choose a reason for your feedback

Your comments

Your feedback helps us to improve this website. Do not give any personal information because we cannot reply to you directly.